Author's Reply to Peronard and Mayntz: "SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect"

Am J Cardiovasc Drugs. 2024 Dec 16. doi: 10.1007/s40256-024-00707-8. Online ahead of print.

David Aristizábal-Colorado^{1

2

3}, Martín Ocampo-Posada^{4

5

6}, Wilfredo Antonio Rivera-Martínez^{5

7}, David Corredor-Rengifo^{4

5}, Jorge Rico-Fontalvo^{8

9}, Juan Esteban Gómez-Mesa^{10

11

12}, John Jairo Duque-Ossman^{13

14}, Alin Abreu-Lomba^{5

15}

¹ Department of Internal Medicine, Universidad Libre, Cali, Colombia. dvdrstzbl@gmail.com.
² Internal Medicine Research Group, Universidad Libre, Cali, Colombia. dvdrstzbl@gmail.com.
³ Interamerican Society of Cardiology (SIAC), Mexico City, Mexico. dvdrstzbl@gmail.com.
⁴ Department of Internal Medicine, Universidad Libre, Cali, Colombia.
⁵ Internal Medicine Research Group, Universidad Libre, Cali, Colombia.
⁶ Faculty of Health. Pontificia, Universidad Javeriana, Cali, Colombia.
⁷ Department of Endocrinology, Faculty of Medicine, Universidad de Antioquia, Antioquia, Colombia.
⁸ Department of Nephrology, Faculty of Medicine, Universidad Simón Bolívar, Barranquilla, Colombia.
⁹ Latin American Society of Nephrology and Arterial Hypertension (SLANH), Panamá City, Panamá.
¹⁰ Interamerican Society of Cardiology (SIAC), Mexico City, Mexico.
¹¹ Cardiology Department, Fundación Valle del Lili, Cali, Colombia.
¹² Department of Health Sciences, Universidad Icesi, Cali, Colombia.
¹³ Universidad del Quindío, Armenia, Colombia.
¹⁴ Latin American Federation of Endocrinology (FELAEN), Panamá City, Panamá.
¹⁵ Endocrinology Department, Clínica Imbanaco, Cali, Colombia.

No abstract available

Publication types